A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Phase 1 Completed 9 enrolled Genentech, Inc.

NaSingle-groupOpen-labelTreatment

This will be a multicenter, open-label study enrolling a total of up to 23 patients.

Evaluation	Drug	Modality	Dose	Route
Subject	PRO95780	Unknown	—	Intravenous
Background	Bevacizumab	Monoclonal antibody	—	Intravenous